|
Lipid and lipoprotein metabolism
Citations 261-270 of 549 total displayed.
|
Past content
(since Jan 1999):
|
- Coronary Heart Disease
High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial
- Sotirios Tsimikas, Joseph L. Witztum, Elizabeth R. Miller, William J. Sasiela, Michael Szarek, Anders G. Olsson, Gregory G. Schwartz for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators
Circulation 2004;110:1406-1412; published online before print as doi:10.1161/01.CIR.0000141728.23033.B5
[Abstract]
[Full text]
- Vascular Medicine
Combined Adipocyte-Macrophage Fatty Acid–Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E–Deficient Mice
- Jeffrey B. Boord, Kazuhisa Maeda, Liza Makowski, Vladimir R. Babaev, Sergio Fazio, MacRae F. Linton, and Gökhan S. Hotamisligil
Circulation 2004;110:1492-1498; published online before print as doi:10.1161/01.CIR.0000141735.13202.B6
[Abstract]
[Full text]
- Articles
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
- Marcello Tonelli, Chris Isles, Gary C. Curhan, Andrew Tonkin, Marc A. Pfeffer, James Shepherd, Frank M. Sacks, Curt Furberg, Stuart M. Cobbe, John Simes, Timothy Craven, and Malcolm West
Circulation published September 13, 2004, doi:10.1161/01.CIR.0000143892.84582.60
[Abstract]
- Articles
Combined Adipocyte-Macrophage Fatty Acid-Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E-Deficient Mice
- Jeffrey B. Boord, Kazuhisa Maeda, Liza Makowski, Vladimir R. Babaev, Sergio Fazio, MacRae F. Linton, and Gökhan S. Hotamisligil
Circulation published September 7, 2004, doi:10.1161/01.CIR.0000141735.13202.B6
[Abstract]
- Articles
High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial
- Sotirios Tsimikas, Joseph L. Witztum, Elizabeth R. Miller, William J. Sasiela, Michael Szarek, Anders G. Olsson, Gregory G. Schwartz for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Circulation published September 7, 2004, doi:10.1161/01.CIR.0000141728.23033.B5
[Abstract]
- Vascular Medicine
Protective Effect of Propylthiouracil Independent of Its Hypothyroid Effect on Atherogenesis in Cholesterol-Fed Rabbits: PTEN Induction and Inhibition of Vascular Smooth Muscle Cell Proliferation and Migration
- Wei-Jan Chen, Kwang-Huei Lin, Ying-Ju Lai, Su-Hui Yang, and Jong-Hwei S. Pang
Circulation 2004;110:1313-1319; published online before print as doi:10.1161/01.CIR.0000140764.15398.F3
[Abstract]
[Full text]
- Articles
Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study
- S. Matthijs Boekholdt, Jan-Albert Kuivenhoven, Nicholas J. Wareham, Ron J.G. Peters, J. Wouter Jukema, Robert Luben, Sheila A. Bingham, Nicholas E. Day, John J.P. Kastelein, and Kay-Tee Khaw
Circulation published August 30, 2004, doi:10.1161/01.CIR.0000141730.65972.95
[Abstract]
- Coronary Heart Disease
Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart Disease
- Shui Ping Zhao, Ling Liu, Yan Chun Cheng, Mehdi H. Shishehbor, Ming Hui Liu, Dao Quan Peng, and Yu Ling Li
Circulation 2004;110:915-920; published online before print as doi:10.1161/01.CIR.0000139985.81163.CE
[Abstract]
[Full text]
- Articles
Protective Effect of Propylthiouracil Independent of Its Hypothyroid Effect on Atherogenesis in Cholesterol-Fed Rabbits. PTEN Induction and Inhibition of Vascular Smooth Muscle Cell Proliferation and Migration
- Wei-Jan Chen, Kwang-Huei Lin, Ying-Ju Lai, Su-Hui Yang, and Jong-Hwei S. Pang
Circulation published August 23, 2004, doi:10.1161/01.CIR.0000140764.15398.F3
[Abstract]
- Articles
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial
- Richard B. Devereux, Björn Dahlöf, Eva Gerdts, Kurt Boman, Markku S. Nieminen, Vasilios Papademetriou, Jens Rokkedal, Katherine E. Harris, Jonathan M. Edelman, and Kristian Wachtell
Circulation published August 23, 2004, doi:10.1161/01.CIR.0000141573.44737.5A
[Abstract]
|
|
